{
  "items": "12",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "ZyVersa Therapeutics Delays 10-Q Filing",
      "url": "https://www.msn.com/en-us/money/topstocks/zyversa-therapeutics-delays-10-q-filing/ar-AA1QtlN5?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
      "time_published": "20251128T200911",
      "authors": [],
      "summary": "ZyVersa Therapeutics announced a delay in filing its quarterly report on Form 10-Q for the period ended September 30, 2023. The company cited the need for additional time to finalize its financial statements due to efforts related to its recent reverse stock split and preparations for its merger with Larkspur Health Acquisition Corp. ZyVersa expects to file within the five-calendar-day extension period.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.945140"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.811780"
        },
        {
          "topic": "finance",
          "relevance_score": "0.716049"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.609252"
        }
      ],
      "overall_sentiment_score": -0.286936,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.276626",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Zyversa Therapeutics Faces Financial Challenges Amid Drug Development",
      "url": "https://www.tipranks.com/news/company-announcements/zyversa-therapeutics-faces-financial-challenges-amid-drug-development",
      "time_published": "20251124T050309",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Zyversa Therapeutics (ZVSA) recently released its Q3 earnings, revealing significant financial challenges including a net loss of $24.3 million for the nine months ended September 30, 2025, and a cash reserve of only $0.5 million. The clinical-stage biopharmaceutical company, focused on renal and inflammatory diseases, is exploring additional financing to continue developing its drug candidates despite substantial doubt about its ability to secure necessary capital.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1306769920-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.914766"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.848352"
        }
      ],
      "overall_sentiment_score": -0.746799,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.733008",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "ZyVersa (OTCQB: ZVSA) Records $18.6M R&D Impairment, Updates Cash Position",
      "url": "https://www.stocktitan.net/news/ZVSA/zy-versa-therapeutics-reports-third-quarter-2025-financial-gwqfx0a5r7f2.html",
      "time_published": "20251119T180955",
      "authors": [
        "NULL"
      ],
      "summary": "ZyVersa Therapeutics reported a Q3 2025 net loss of $19.8 million, primarily driven by an $18.6 million impairment of in-process research and development. The company ended the quarter with only $0.5 million in cash, indicating a need for additional financing to sustain operations. Despite the significant loss, the stock experienced a moderate positive market reaction, gaining 3.70% on the day this news was published.",
      "banner_image": "https://ml.globenewswire.com/media/OTY5NzQ2Y2EtMTgyYi00ZTRhLWE4NGMtZWI2ZWQxMzY4MzBkLTEyNTYwNjktMjAyNS0xMS0xOS1lbg==/tiny/ZyVersa-Therapeutics.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929092"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.945315"
        },
        {
          "topic": "finance",
          "relevance_score": "0.840498"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.649927"
        }
      ],
      "overall_sentiment_score": -0.64013,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.616957",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results",
      "url": "https://www.globenewswire.com/news-release/2025/11/19/3191443/0/en/ZyVersa-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html",
      "time_published": "20251119T162000",
      "authors": [],
      "summary": "ZyVersa Therapeutics reported its financial results for the third quarter ended September 30, 2025, detailing a cash balance of $0.5 million and a pre-tax loss of $20.7 million. The company is actively seeking additional financing to support its operations and pipeline development, which includes VAR 200 for kidney diseases and IC 100 for chronic inflammatory conditions. Much of the increased net loss was attributed to an $18.6 million impairment of research and development assets.",
      "banner_image": "https://ml.globenewswire.com/media/OTY5NzQ2Y2EtMTgyYi00ZTRhLWE4NGMtZWI2ZWQxMzY4MzBkLTEyNTYwNjktMjAyNS0xMS0xOS1lbg==/tiny/ZyVersa-Therapeutics.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.816663"
        },
        {
          "topic": "finance",
          "relevance_score": "0.635147"
        }
      ],
      "overall_sentiment_score": 0.001671,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "0.312993",
          "ticker_sentiment_score": "0.038013",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market",
      "url": "https://www.investing.com/news/sec-filings/zyversa-therapeutics-to-be-delisted-from-nasdaq-trading-to-move-to-otc-market-93CH-4138201",
      "time_published": "20250716T125400",
      "authors": [
        "Investing.com"
      ],
      "summary": "ZyVersa Therapeutics (NASDAQ: ZVSA) announced it will be delisted from the Nasdaq Capital Market due to noncompliance with the minimum bid price requirement. The company's stock has already fallen 87% over the past year and will begin trading on the Pink Limited Market operated by OTC Markets Group Inc. under the symbol ZVSA around July 17, 2025.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.948855"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.908062"
        }
      ],
      "overall_sentiment_score": 0.036913,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "0.305328",
          "ticker_sentiment_score": "0.013712",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move",
      "url": "https://www.tipranks.com/news/company-announcements/zyversa-therapeutics-faces-nasdaq-delisting-plans-pink-market-move",
      "time_published": "20250715T190919",
      "authors": [
        "NULL"
      ],
      "summary": "ZyVersa Therapeutics (ZVSA) is facing delisting from the Nasdaq Capital Market due to non-compliance with minimum bid price requirements, with trading to be suspended on July 17, 2025. The company plans to move its trading to the Pink Limited Market under the same symbol, ZVSA, starting around July 17, 2025. This move is expected to limit market liquidity and potentially affect stock prices.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1279492897-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.937065"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.814117"
        },
        {
          "topic": "finance",
          "relevance_score": "0.709891"
        }
      ],
      "overall_sentiment_score": -0.747837,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.745394",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator\u2122 VAR 200 in a Patient with ApoCII Amyloidosis",
      "url": "https://finance.yahoo.com/news/zyversa-therapeutics-supports-fda-authorized-115200669.html",
      "time_published": "20250708T210852",
      "authors": [
        "NULL"
      ],
      "summary": "ZyVersa Therapeutics announced that the FDA has authorized Emergency Compassionate Use of its Cholesterol Efflux Mediator\u2122 VAR 200 for a patient suffering from ApoCII amyloidosis, a rare kidney disease. The patient, whose kidney disease continues to progress despite standard treatments, will receive VAR 200 under the care of Dr. Alessia Fornoni. This emergency use is based on promising preclinical results of VAR 200 in kidney disease models and its potential to alleviate lipid accumulation and proteinuria.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2cfPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.421036,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.409469",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Biotech ZyVersa Raises $2M in Strategic Warrant Deal to Advance Drug Development Pipeline",
      "url": "https://www.stocktitan.net/news/ZVSA/zy-versa-therapeutics-announces-a-warrant-inducement-transaction-for-m0noijbsdaly.html",
      "time_published": "20250708T050309",
      "authors": [],
      "summary": "ZyVersa Therapeutics has secured $2 million in gross proceeds through a warrant inducement agreement with an institutional investor. This deal involves the immediate exercise of existing Series A-2 and A-3 Warrants at a reduced price of $0.67, with the investor also receiving new Series A-4 unregistered warrants for up to 6,124,930 shares. While providing much-needed capital for working capital and general corporate purposes, the highly dilutive nature of the transaction suggests potential financial constraints for the clinical-stage biopharmaceutical company.",
      "banner_image": "https://ml.globenewswire.com/media/ZmJhMGIwYTMtMTFkYi00NTk2LWE4NzAtMjFiZjhmODY3ZmFjLTEyNTYwNjktMjAyNS0wNy0wOC1lbg==/tiny/ZyVersa-Therapeutics.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.903449"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.838952"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.705708"
        },
        {
          "topic": "finance",
          "relevance_score": "0.607046"
        }
      ],
      "overall_sentiment_score": -0.433284,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.403018",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?",
      "url": "https://www.sahmcapital.com/news/content/why-did-zyversa-therapeutics-stock-shoot-higher-on-tuesday-2025-07-08",
      "time_published": "20250708T050309",
      "authors": [
        "Benzinga News"
      ],
      "summary": "ZyVersa Therapeutics stock surged on Tuesday due to its involvement in providing regulatory and product support for the FDA-authorized Emergency Compassionate Use of VAR 200 in a patient with ApoCII amyloidosis. The company also announced a warrant inducement agreement with an institutional investor, generating $2 million in gross proceeds. VAR 200 is an injectable drug in Phase 2 development for kidney diseases, with initial proof-of-concept expected from a diabetic kidney disease trial.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.903722"
        }
      ],
      "overall_sentiment_score": 0.52909,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.541333",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ZyVersa Therapeutics Inc. (ZVSA) reports earnings",
      "url": "https://qz.com/zyversa-therapeutics-inc-zvsa-reports-earnings-1851772690",
      "time_published": "20250327T050309",
      "authors": [
        "Quartz Intelligence Newsroom"
      ],
      "summary": "ZyVersa Therapeutics Inc. (ZVSA) has filed its Form 10-K for the fiscal year ended December 31, 2024, reporting a net loss of $9.4 million, a significant reduction from the previous year. The company saw decreased research and development, and general and administrative expenses. ZyVersa continues to advance its drug candidates, VAR 200 and IC 100, while navigating financing challenges and regulatory risks.",
      "banner_image": "https://qz.com/cdn-cgi/image/width=1920,quality=85,format=auto/https://assets.qz.com/media/default.jpg",
      "source": "qz.com",
      "category_within_source": "General",
      "source_domain": "qz.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.903801"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.840760"
        }
      ],
      "overall_sentiment_score": -0.274386,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.251642",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market",
      "url": "https://www.globenewswire.com/news-release/2025/03/06/3038148/0/en/ZyVersa-Therapeutics-Inc-Announces-Pricing-of-2-0-Million-Private-Placement-Priced-At-The-Market.html",
      "time_published": "20250306T190919",
      "authors": [
        "NULL"
      ],
      "summary": "ZyVersa Therapeutics, Inc. announced a private placement of common stock and warrants with a single healthcare-focused U.S. institutional investor, raising approximately $2.0 million. The company plans to use the net proceeds for general working capital. The agreement also includes an amendment to reduce the exercise price of certain existing warrants, subject to shareholder approval.",
      "banner_image": "https://ml.globenewswire.com/media/ZDM1MGQyYjMtZjIzNy00YzUzLWJmZDUtZWJjM2Q2NmRjODdmLTEyNTYwNjk=/tiny/ZyVersa-Therapeutics.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.940701"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.842427"
        }
      ],
      "overall_sentiment_score": 0.296338,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.260991",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker \"ZVSA\")",
      "url": "https://www.prnewswire.com/news-releases/zyversa-therapeutics-inc-and-larkspur-health-acquisition-corp-close-business-combination-zyversa-expected-to-begin-trading-on-nasdaq-december-13-2022-ticker-zvsa-301700957.html",
      "time_published": "20221212T210500",
      "authors": [],
      "summary": "ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. have announced the closing of their business combination. The combined company will operate as ZyVersa Therapeutics, Inc., and its common stock is expected to begin trading on Nasdaq under the ticker symbol \"ZVSA\" on December 13, 2022. This merger is anticipated to provide funding for ZyVersa to advance its clinical programs for VAR 200 and IC 100.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.921025"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.915992"
        },
        {
          "topic": "finance",
          "relevance_score": "0.800139"
        }
      ],
      "overall_sentiment_score": 0.42554,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZVSA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.440867",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}